Vote Recommendation | Economic Freedom | Property Rights | Personal Responsibility | Limited Government | Individual Liberty |
---|---|---|---|---|---|
Yes | Neutral | Neutral | Neutral | Positive | Positive |
No significant fiscal implication to the State is anticipated.
No fiscal implication to units of local government is anticipated.
The bill would authorize terminally ill patients or patients
with severe chronic diseases, who have exhausted all viable treatment options,
to access experimental drugs that have not yet been approved by the United
States Food and Drug Administration (FDA). The bill specifically refers to
drugs that have passed the first phase (safety phase) but have not passed the
second phase (efficacy test) of the FDA drug approval process.
The executive commissioner would be required to adopt rules
specifying treatments patients could access. The executive commissioner would
have the authorization to approve for treatment experimental drugs that have
completed or are in the appropriate phase of a clinical trial in another
country.